The glial marker YKL-40 is decreased in synucleinopathies

2013 ◽  
Vol 28 (13) ◽  
pp. 1882-1885 ◽  
Author(s):  
Bob Olsson ◽  
Radu Constantinescu ◽  
Björn Holmberg ◽  
Niels Andreasen ◽  
Kaj Blennow ◽  
...  
Keyword(s):  
Glial Marker

scholarly journals Mood Disorders Are Glial Disorders: Evidence from In Vivo Studies

2010 ◽  
Vol 2010 ◽  
pp. 1-7 ◽  
Author(s):  
Matthias L. Schroeter ◽  
Hashim Abdul-Khaliq ◽  
Julia Sacher ◽  
Johann Steiner ◽  
Ingolf E. Blasig ◽  
...  
Keyword(s):  
Mood Disorders ◽  
Neuron Specific Enolase ◽  
In Vivo Studies ◽  
Diagnostic Biomarker ◽  
Major Depressive ◽  
Neuronal Marker ◽  
Serum S100b ◽  
Antidepressive Treatment ◽  
Glial Marker

It has recently been suggested that mood disorders can be characterized by glial pathology as indicated by histopathological postmortem findings. Here, we review studies investigating the glial marker S100B in serum of patients with mood disorders. This protein might act as a growth and differentiation factor. It is located in, and may actively be released by, astro- and oligodendrocytes. Studies consistently show that S100B is elevated in mood disorders; more strongly in major depressive than bipolar disorder. Successful antidepressive treatment reduces S100B in major depression whereas there is no evidence of treatment effects in mania. In contrast to the glial marker S100B, the neuronal marker protein neuron-specific enolase is unaltered. By indicating glial alterations without neuronal changes, serum S100B studies confirm specific glial pathology in mood disorders in vivo. S100B can be regarded as a potential diagnostic biomarker for mood disorders and as a biomarker for successful antidepressive treatment.

Effects of subacute toluene exposure on neuronal and glial marker proteins in rat brain

Toxicology ◽  
1990 ◽  
Vol 61 (2) ◽  
pp. 109-117 ◽  
Author(s):  
Jian Huang ◽  
Kanefusa Kato ◽  
Eiji Shibata ◽  
Naomi Hisanaga ◽  
Yuichiro Ono ◽  
...  
Keyword(s):  
Rat Brain ◽  
Marker Proteins ◽  
Toluene Exposure ◽  
Glial Marker

Regional expression of the radial glial marker vimentin at different stages of the kindling process

2004 ◽  
Vol 61 (1-3) ◽  
pp. 141-151 ◽  
Author(s):  
Toshitaka Nakagawa ◽  
Tetsuji Miyazaki ◽  
Osamu Miyamoto ◽  
Najma A. Janjua ◽  
Toshiyuki Hata ◽  
...  
Keyword(s):  
Radial Glial ◽  
Glial Marker

scholarly journals Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient–Control Differences

2021 ◽  
Vol 89 (3) ◽  
pp. e5-e8 ◽  
Author(s):  
Pontus Plavén-Sigray ◽  
Granville J. Matheson ◽  
Jennifer M. Coughlin ◽  
Sina Hafizi ◽  
Heikki Laurikainen ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Patient Control ◽  
Glial Marker

scholarly journals T7. UPDATED INDIVIDUAL PARTICIPANT DATA META-ANALYSIS CONFIRMS LOWER LEVELS OF THE GLIAL MARKER TSPO IN PSYCHOSIS PATIENTS

2020 ◽  
Vol 46 (Supplement_1) ◽  
pp. S233-S233
Author(s):  
Pontus Plavén-Sigray ◽  
Granville Matheson ◽  
Jennifer Coughlin ◽  
Sina Hafizi ◽  
Heikki Laurikainen ◽  
...  
Keyword(s):  
Disease Duration ◽  
Meta Analysis ◽  
Strong Support ◽  
First Episode ◽  
Individual Participant Data ◽  
Control Subjects ◽  
Episode Psychosis ◽  
Individual Participant ◽  
Healthy Control ◽  
Glial Marker

Abstract Background Treatment targeting the immune system is a promising new approach in schizophrenia. In search for tools for stratification and treatment monitoring, much effort has been invested in the use of positron emission tomography (PET) and radioligands binding to a glial marker, the 18 kDa translocator protein (TSPO). We previously demonstrated lower TSPO in psychosis patients in an individual participant data (IPD) meta-analysis of studies using second generation TSPO radioligands (Plavén-Sigray et al., 2018). Subsequently, a summary-statistics meta-analysis, including one newly published study, showed no difference (Marques et al., 2019). Here, the aim was to repeat the IPD analysis including this new sample, and an additional unpublished dataset in first episode psychosis patients. The primary objective was to re-evaluate the hypotheses of 1) higher or 2) lower or 3) no difference in radioligand binding between patients and healthy control subjects. Secondary objectives were to assess the effects of antipsychotic medication on TSPO binding, as well as relationships between TSPO binding and disease duration and symptom measures. Methods Individual participant data were obtained from PET studies that 1) used a second generation TSPO radioligand, 2) reported distribution volume (VT) values in brain in patients with psychosis as compared to healthy controls, and 3) reported TSPO affinity type of all participants. The outcome measure was VT in frontal cortex (FC), temporal cortex (TC) and hippocampus (HIP). Bayes factors (BF) were applied to examine the relative support for higher, lower, or no-change of TSPO levels in patients compared to healthy controls. Results Individual participant data from seven studies were included, amounting to 99 patients with first-episode psychosis or schizophrenia and 109 healthy control subjects. In all regions investigated, BF showed moderate to strong support (BF > 5) for lower VT in patients as compared to no difference, and strong support (BF > 10) for lower VT compared to higher VT in patients. Mean patient-control differences in standardized VT values were -0.41 for FC (95%CI -0.67 to -0.15, p = 0.0022), -0.38 for TC (95%CI -0.64 to -0.12, p = 0.0048) and -0.53 for HIP (95% CI -0.79 to -0.27, p = 0.0001). The mean change in standardized VT due to medication was 0.10 for FC (CI95% -0.10 to 0.30, p = 0.615), -0.08 for TC (CI95% -0.32 to 0.48, p = 0.666) and 0.08 for HIP (CI95% -0.46 to 0.30, p = 0.682). No association was observed between VT and disease duration or symptom levels (all p > 0.526). Discussion In this updated IPD meta-analysis including two new datasets, we found moderate to strong support for lower TSPO in psychosis patients compared to control subjects. In vitro data has shown a lack of correspondence between TSPO and pro-inflammatory activation, also recently confirmed in a post-mortem study in schizophrenia. Hence, based on the present results no firm conclusions can be made regarding the pro- versus anti-inflammatory status of glial cells in psychosis patients. Additional work is needed to understand the biological relevance of the observed lower TSPO in patients.

Neuronal and Glial Marker Proteins in the Evaluation of the Protective Action of MK 801

1991 ◽  
Vol 56 (6) ◽  
pp. 1957-1961 ◽  
Author(s):  
K. G. Haglid ◽  
S. Wang ◽  
A. Hamberger ◽  
A. Lehmann ◽  
C. J. Moller
Keyword(s):  
Protective Action ◽  
Mk 801 ◽  
Marker Proteins ◽  
Glial Marker

BIOM-09. MYO-INOSITOL LEVELS ON MR SPECTROSCOPY CAN PREDICT FAILURE OF ANTI-ANGIOGENIC TREATMENT IN RECURRENT GLIOBLASTOMA

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi11-vi12
Author(s):  
Mohamed El-Abtah ◽  
Michael Wenke ◽  
Pratik Talati ◽  
Melanie Fu ◽  
Daniel Kim ◽  
...  
Keyword(s):  
Spectroscopic Data ◽  
Recurrent Glioblastoma ◽  
Term Survival ◽  
Prospective Longitudinal Study ◽  
Normal Appearing White Matter ◽  
Echo Time ◽  
Short Echo Time ◽  
Prospective Longitudinal ◽  
The Brain ◽  
Glial Marker

Abstract BACKGROUND Recurrent glioblastoma (rGBM) patients are often treated with anti-angiogenic agents such as bevacizumab (BEV). Despite therapeutic promise, conventional MR methods fail to determine which patients may not benefit. PURPOSE: The purpose of this study was to utilize magnetic resonance spectroscopic imaging (MRSI) with intermediate and short echo time to generate corrected Myo-inositol normalized by contralateral creatine (mI/c-Cr) in patients with rGBM treated with BEV and investigate whether it can predict survivorship prior to BEV initiation (baseline) and at 1-day, 4-weeks, and 8-weeks thereafter. METHODS We conducted a prospective, longitudinal study and evaluated spectroscopic data of myo-inositol (mI), a glial marker and osmoregulator within the brain, normalized to contralateral-creatine (mI/c-Cr) in the intratumoral, contralateral normal appearing white matter, and peritumoral volumes of rGBM patients. Area under the ROC curve (AUC) was calculated for all volumes at baseline, 1-day, 4-weeks, and 8-weeks after treatment to determine mI/c-Cr’s ability to predict survivorship. RESULTS 21 participants (62 ± 12 years, 15 men) were evaluated. Lower mI/c-Cr in the tumor prior to and during BEV treatment predicted poor survivorship, with ROC analyses illustrating an AUC of 0.75 at baseline, 0.87 at 1-day, and 1 at 8 weeks. Lower levels of mI/c-Cr were also observed in the contralateral and the peritumoral volumes for shorter-term survivors. In the contralateral volume, lower mI/Cr was predictive of shorter-term survival at baseline and all other timepoints. Within the peritumoral volume, lower mI/c-Cr was predictive of shorter-term survival at baseline (AUC=0.80), 1-day (AUC=0.93), and 4-weeks (AUC=0.68). CONCLUSIONS Lower levels of mI/c-Cr within intratumoral, contralateral, and peritumoral volumes were predictive of poor survivorship and anti-angiogenic treatment failure as early as one month before BEV treatment. Acquiring MRSI alongside conventional MR imaging modalities can convey critical information regarding tumor microenvironment that informs management of patients with rGBM.

Developmental changes in content of glial marker proteins in rats exposed to protein malnutrition

2008 ◽  
Vol 1187 ◽  
pp. 33-41 ◽  
Author(s):  
Ana Maria Feoli ◽  
Marina C. Leite ◽  
Ana Carolina Tramontina ◽  
Francine Tramontina ◽  
Thais Posser ◽  
...  
Keyword(s):  
Protein Malnutrition ◽  
Developmental Changes ◽  
Marker Proteins ◽  
Glial Marker

Comparative Study of Glial Marker Proteins in the Hypoplastic Cerebellum of Jaundiced Gunn Rats

1988 ◽  
Vol 50 (3) ◽  
pp. 717-721 ◽  
Author(s):  
Sachiko Aono ◽  
Hiroshi Sato ◽  
Reiji Semba ◽  
Shigeo Kashiwamata ◽  
Kanefusa Kato ◽  
...  
Keyword(s):  
Comparative Study ◽  
Gunn Rats ◽  
Marker Proteins ◽  
Glial Marker

A glial cell arises from an additional division within the mechanosensory lineage during development of the microchaete on the Drosophila notum

Development ◽  
1999 ◽  
Vol 126 (20) ◽  
pp. 4617-4622 ◽  
Author(s):  
G.V. Reddy ◽  
V. Rodrigues
Keyword(s):  
Glial Cell ◽  
Cell Fate ◽  
Cell Lineage ◽  
The Other ◽  
Sensory Cells ◽  
Cell Fate Specification ◽  
Fate Specification ◽  
Low Levels ◽  
Proposed Modification ◽  
Glial Marker

We have used different cell markers to trace the development of the sensory cells of the thoracic microchaete. Our results dictate a revision in the currently accepted model for cell lineage within the mechanosensory bristle. The sensory organ progenitor divides to form two secondary progenitors: PIIa and PIIb. PIIb divides first to give rise to a tertiary progenitor-PIII and a glial cell. This is followed by division of PIIa to form the shaft and socket cells as described before. PIII expresses high levels of Elav and low levels of Prospero and divides to produce neuron and sheath. Its sibling cell expresses low Elav and high Prospero and is recognized by the glial marker, Repo. This cell migrates away from the other cells of the lineage following differentiation. The proposed modification in lineage has important implications for previous studies on sibling cell fate choice and cell fate specification in sensory systems.

Sign in / Sign up

Export Citation Format

Share Document